Overview
Zydus Hospitals, Ahmedabad announced implementation of novel targeted medicines for allergies and autoimmune diseases, aiming to reduce reliance on systemic steroids.
Clinical Cases Highlighted
- A 9‑year‑old boy with severe cow‑milk allergy experienced anaphylactic shock after ingesting ghee. After nine years of unmanaged allergy, Dr. Kunal Chandwar initiated omalizumab, the only US‑FDA‑approved biologic for IgE‑mediated food allergy. Using a “milk ladder” approach, the child gradually re‑introduced milk‑containing foods and, after two years, can tolerate small amounts of biscuits and cakes, though complete avoidance remains necessary.
- A 27‑year‑old man with psoriasis affecting ~90 % of his skin and concurrent psoriatic arthritis was treated with ixekizumab, an IL‑17 inhibitor. After 1.5 months, skin involvement improved by more than 80 % without steroids, and no new lesions appeared.
- An 18‑year‑old woman with lupus nephritis progressed to lupus myocarditis, with ejection fraction falling to 10 %. She required six months of dialysis while receiving rituximab. Following rituximab therapy, both cardiac and renal function returned to normal.
- An 18‑year‑old woman with ANCA‑associated vasculitis affecting skin and lungs received rituximab for six months, leading to gradual recovery. Two biologics are approved for ANCA vasculitis: rituximab and mepolizumab (eosinophilic form).
Therapeutic Landscape
- Biologics such as omalizumab, ixekizumab, rituximab, mepolizumab, benralizumab, and dupilumab target specific immune pathways (IgE, IL‑17, B‑cells, eosinophils, IL‑4/IL‑13) and are increasingly preferred over broad‑spectrum steroids.
- Seven US‑FDA‑approved biologics are available for severe asthma; four for atopic dermatitis; more than ten for psoriasis, each acting on distinct inflammatory pathways.
- CAR‑T cell therapy, which modifies a patient’s own immune cells to eliminate pathogenic B‑cells, is emerging as a novel approach for autoimmune diseases.
Diagnostic Capability
Zydus Hospitals provides a complete diagnostic work‑up supported by an in‑house laboratory capable of comprehensive allergy profiling, enabling precise identification of the pathogenic immune pathway and selection of the appropriate targeted therapy.
Safety and Supervision
All biologic treatments require specialist supervision; self‑administration or unsupervised “milk ladder” attempts are discouraged.